Mass drug administration (MDA) of antibiotics to all children in a community or population has the potential to reduce infectious diseases and reduce childhood mortality globally. However, MDA requires weighing near-term gains against longer-term risks of antibiotic resistance, which would impair treatment of serious bacterial infections; fairly distributing benefits and risks among individuals, communities, and whole societies; obtaining informed consent, and engaging the community.